Sen­a­tors call on FDA to ad­dress 'del­uge of mis­lead­ing pro­mo­tion­s' on so­cial me­dia

Sen­a­tors across both sides of the aisle are call­ing for a “swift” up­date to the FDA’s guid­ance on pre­scrip­tion drug pro­mo­tion.

Sens. Mike Braun (R-IN) and Dick Durbin (D-IL) said Wednes­day in a let­ter to FDA com­mis­sion­er Robert Califf that so­cial me­dia has giv­en rise to an “alarm­ing pro­lif­er­a­tion of dan­ger­ous and mis­lead­ing con­tent” around pre­scrip­tion med­i­cines. They point­ed to what they say are “gap­ing holes” in the FDA’s over­sight of di­rect-to-con­sumer pro­mo­tions on so­cial me­dia, and urged the agency to clar­i­fy its poli­cies around new­er plat­forms and in­flu­encers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER